TRANSPLANTATION TESTING

Two special genetic regions with sufficient sequence variability for identity testing include the human leukocyte antigen (HLA) loci within the major histocompatibility complex (MHC) and the mitochondrial DNA. The HLA loci described in the Transplantation Testing section later in this... 

Costard-Jackle, A., and Fowler, M. B. (1992). Influence of preoperative pulmonary artery pressure on mortality after heart transplantation Testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J. Am. Coll. Cardiol. 19, 48-54. 

Experiments with testieular extract has more or less enjoyed a ehequered eareer. Veronoff successfully transplanted tested from monkeys into elderly men and claimed to rejuvenate them. Likewise, ligature of vas deferens whieh is known to cause atrophy of spermatogenie tissue and indireetly hypertrophy ofintestinal tissue which secrete testosterone. Another researeher Steinaeh earned out similar studies by ligaturing the vas deferens and obtained identical results. 

Apart from these two Vertex compounds, only one other caspase inhibitor, BDN-6556, has been used in clinical trials. This compound belongs to the class of oxamyl dipeptides and was originally developed by Idun Pharmaceuticals (taken over by Pfizer). It is the only pan-caspase inhibitor that has been evaluated in humans. BDN-6556 displays inhibitory activity against all tested human caspases. It is also an irreversible, caspase-specific inhibitor that does not inhibit other major classes of proteases, or other enzymes or receptors. The therapeutic potential of BDN-6556 was first evaluated in several animal models of liver disease because numerous publications suggested that apoptosis contributes substantially to the development of some hepatic diseases, such as alcoholic hepatitis, hepatitis B and C (HBV, HCV), non-alcoholic steato-hepatitis (NASH), and ischemia/reperfusion injury associated with liver transplant. Accordingly, BDN-6556 was tested in a phase I study. The drug was safe and... 

The first mouse monoclonal antibody specific for human CD3 was produced in 1979 and named orthoclone OKT3. Aside from its use in the laboratory, OKT3 became the first anti-CD3 antibody to be utilized in transplantation medicine, but its wider application was hampered by its immunogenic and mitogenic properties (reviewed in [6]). Consequently, humanized and engineered anti-CD3 antibodies were developed to circumvent these limitations (Table 1). Since T cells and the TCR are involved in many immunological diseases, it is not surprising that the application of CD3 antibodies is not restricted to the field of transplantation. For example, CD3 antibodies are tested in clinical studies of diseases such as autoimmune diabetes (type 1 diabetes), immune-mediated inflammatory arthritis and inflammatory bowel disease [7]. 

Occasional exercise testing is conducted in order to ascertain disease prognosis or suitability for heart transplant. Even though these tests can demonstrate improvement in heart function and therefore slowed disease progression, patient symptoms may not improve. 

Cyclosporine is a cyclic polypeptide immunosuppressant typically used to prevent organ rejection in transplant patients. Its use is restricted to patients with fulminant or refractory symptoms in patients with active IBD. Significant toxicides associated with cyclosporine are nephrotoxicity, risk of infection, seizures, hypertension, and liver function test abnormalities.1,13,14... 

About 40% of this population express markers of oligodendrocytes, and a similar proportion have astrocytic markers. To test the potential of these cells in vitro, ES cells propagated in this fashion were transplanted into the spinal cord or cerebral ventricles of myelin-deficient rats. Two weeks after transplantation, ES derived cells were present in the dorsal columns of the spinal cord both at the implant and several millimeters in both directions from that site. The mouse origin of the ES cells transplanted into rat was confirmed by analysis of mouse satellite DNA in the grafts. Similarly, intraventricular transplanted cells formed myelin in multiple brain regions [29]. These and other results support the further study of stimulated ES cells for potential therapies in the nervous system. 

---